Lipertance

Amlodipine besilate, Perindopril arginine and Atorvastatin calcium trihydrate, the active ingredients in Lipertance, are a combination of a calcium channel blocker, an ACE inhibitor and an HMG‑CoA reductase inhibitor presented as an oral tablet for oral use. It treats hypertension and hyperlipidaemia, and is used to reduce cardiovascular risk in adults who need simultaneous blood‑pressure and cholesterol control.

GNH USA supplies Lipertance as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lipertance combines antihypertensive and lipid‑lowering mechanisms to manage cardiovascular risk.

- Hypertension: lowers systolic and diastolic blood pressure, improving vascular tone and reducing the workload on the heart. - Hyperlipidaemia: decreases low‑density lipoprotein (LDL) cholesterol and total cholesterol, helping to achieve lipid‑profile targets. - Cardiovascular risk reduction: lowers the incidence of major adverse cardiac events in patients with combined hypertension and dyslipidaemia.

Lipertance may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Headache: mild to moderate headache. - Peripheral edema: swelling of ankles or feet. - Dizziness: light‑headedness, especially on standing. - Gastrointestinal discomfort: nausea, abdominal pain or dyspepsia. - Cough: dry or productive cough. - Fatigue: feeling unusually tired.

Serious or Rare Side Effects: - Angio‑edema: rapid swelling of face, lips, tongue or airway. - Hepatotoxicity: elevated liver enzymes or jaundice. - Rhabdomyolysis: muscle pain with dark urine indicating severe muscle breakdown.

Before prescribing Lipertance, clinicians should consider several safety measures.

- Blood pressure monitoring: check blood pressure regularly after initiating therapy. - Liver function assessment: evaluate hepatic enzymes before and during treatment. - Renal function evaluation: adjust use in patients with impaired kidney function. - Concomitant drug review: avoid use with strong CYP3A4 inhibitors without supervision. - Pregnancy and lactation: contraindicated unless benefits outweigh risks; consult a healthcare provider. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Lipertance can interact with other medicines; awareness of major and moderate interactions helps prevent adverse outcomes.

Major Interactions (Avoid): - Dual ACE inhibitor or ARB therapy: may cause excessive hypotension or renal impairment. - Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): increase atorvastatin levels, raising risk of myopathy. - Non‑steroidal anti‑inflammatory drugs (NSAIDs) with perindopril: heightened risk of kidney injury.

Moderate Interactions (Monitor Closely): - Simvastatin or lovastatin: combined with atorvastatin may increase statin‑related toxicity. - Diuretics: may enhance antihypertensive effect, requiring blood‑pressure monitoring. - Calcium‑channel blocker combinations: additive vasodilatory effect may cause dizziness.